AMN Healthcare (AMN) Q2 2026 earnings review
Core Growth Emerges from the Post-Strike Hangover
After a massive $722M labor disruption windfall in Q1, AMN Healthcare's Q2 revenue normalized to $673.2M (+2% YoY), beating guidance. The most encouraging signal is the core Nurse and Allied segment, which grew 11% YoY, marking its second consecutive quarter of volume and revenue expansion. However, the underlying margin profile is deteriorating. While reported Q2 gross margins looked robust at 30.6% (inflated by strike true-ups), Q3 guidance anticipates a sharp drop to 27.0-27.5% alongside revenue stagnation. With Locum Tenens and Technology segments still shrinking, the company is fighting to offset high-margin declines with lower-margin volume.
🐂 Bull Case
The company's largest division has definitively bottomed. Travel nurse staffing grew 10% YoY and Allied grew 8% YoY, proving that volume demand is stabilizing as hospital contract labor usage normalizes.
Despite a negative operating cash flow quarter driven entirely by refunding strike-related client deposits, the balance sheet remains exceptionally clean with a 1.5x leverage ratio and $362M in cash, allowing for targeted M&A.
🐻 Bear Case
Q3 adjusted EBITDA margin guidance of 6.5%-7.0% represents a severe deceleration. The company is trading high-margin Tech and Physician revenues for lower-margin Nurse & Allied volumes.
The Technology segment fell 15% YoY (VMS down 20%), and Locum Tenens dropped 8%. Until these high-margin segments reverse their declines, earnings leverage will remain elusive.
⚖️ Verdict: ⚪
Neutral. Management successfully navigated a historic labor disruption event in Q1 and is now showing legitimate YoY volume growth in its core business. However, deteriorating Q3 margin guidance and persistent structural weakness in Locums and VMS prevent a more bullish outlook.
Key Themes
Nurse & Allied Sustains Core Recovery
The Nurse & Allied Solutions segment confirmed its recovery, delivering $422M in revenue (+11% YoY). Stripping out the $25M in remaining labor disruption revenue, underlying travel nurse staffing (+10%) and allied divisions (+8%) are accelerating. This reflects a broader macro stabilization where healthcare organizations are increasingly utilizing contingent labor as wage premiums over permanent staff narrow.
Leadership Search Rebound and AI Integrations
While the broader Physician and Leadership segment declined, the Search sub-segment surged 27% YoY. Management is deploying new tech assets to sustain this, integrating the recently acquired ESSENTIAL Leadership Assessment and Jaide Health to deepen client relationships and embed AI-native language access into their enterprise workflows.
Optical Illusion in Q2 Gross Margins
A critical contradiction to the positive Q2 earnings narrative is the margin quality. Consolidated gross margin expanded 80 bps YoY to 30.6%. However, this was artificially elevated by reserve releases and billing true-ups from Q1's massive labor disruptions. Management's Q3 gross margin guidance of 27.0-27.5% reveals the true, reversing trend of the underlying business profitability.
Locum Tenens Continues to Drag
Physician and Leadership Solutions revenue fell 6% YoY to $165M, heavily pressured by an 8% drop in Locum Tenens ($131M). This represents a decelerating trend for a segment that has historically provided margin support, as client spend shifts toward more competitive third-party channels.
Technology Segment Pricing Squeeze
Technology and Workforce Solutions remains a persistent laggard, dropping 15% YoY to $87M. VMS revenue collapsed 20% YoY, and Language Services fell 8% YoY to $70M. The decline in Language Services is specifically driven by aggressive competitive pricing pressure, which management is attempting to combat through technology bolt-ons rather than price matching.
Cash Flow Optics Distorted by Q1 Strikes
Operating Cash Flow swung to negative $190M in Q2. This is not a structural cash burn, but a mechanical reversing of working capital as AMN refunded $250M+ in client deposits collected during the Q1 labor disruption events. With $117M in deposits remaining to be settled, cash flow metrics will remain noisy through Q3.
Other KPIs
Stable and highly favorable. The leverage ratio dropped to 1.5x, down from 3.3x at the end of 2025. Total debt sits at $750M with nothing drawn on the revolving credit facility, affording management significant flexibility for M&A (like the Jaide Health acquisition) despite near-term margin pressure.
SG&A as a percentage of revenue was 21.9%, improving from 23.5% in the prior year. The year-over-year nominal decrease was driven by lower provision for expected credit losses and lower employee headcount, signaling that cost-cutting measures are actively cushioning the bottom line against gross margin compression.
Guidance
Stable YoY, but decelerating sequentially. The midpoint of $647.5M represents a 1-3% YoY increase, but a ~4% drop from Q2 2026. This reflects the total wash-out of labor disruption revenue and standard seasonal patterns.
Decelerating aggressively from the 10.9% reported in Q2. This confirms that the Q2 margin profile was inflated by one-time billing true-ups and exposes the structural margin drag caused by weakness in the high-margin Technology and Physician segments.
Stable core growth. This confirms that the return to volume growth achieved in H1 2026 is sustainable and not a momentary blip, anchoring the company's revenue floor.
Decelerating. This indicates that VMS client runoff and Language Services pricing pressures have not yet found a bottom.
Key Questions
Language Services Pricing Floor
Language Services revenue fell 8% due to competitive pricing pressure. At what point do you expect this pricing pressure to bottom out, and how is the integration of Jaide Health's AI technology changing client contract renewal discussions?
VMS Client Runoff
VMS revenue declined 20% year-over-year. Is this primarily driven by the ongoing runoff of legacy systems, or are we losing share to integrated MSP competitors? When do we lap these heavy VMS declines?
Capital Allocation and M&A
With leverage down to 1.5x and the balance sheet looking incredibly clean post-strike deposit settlements, how are you prioritizing share buybacks versus further technology tuck-in acquisitions similar to ESSENTIAL and Jaide Health?
Locum Tenens Recovery Path
Locum Tenens revenue dropped 8% YoY. Given the historical strength of this segment, what specific market shifts are driving this, and what is your timeline for returning Locums to YoY growth?